Metastasis heterogeneity presents a significant obstacle to the current developmental paradigm for highly targeted molecular and immune based cancer therapeutics. We sought to establish from a large series of human melanoma metastases whether a determined pattern in cellular heterogeneity exists that may guide future clinical efforts. By profiling for a panel of prototypic melanocyte lineage antigens, we found a non-stochastic site-specific pattern of expression in metastases that was highest in brain, intermediate in soft tissues/lymph nodes, and lowest in visceral sites. Tyrosinase demonstrated a unique expression profile with more frequent loss and an exclusive correlation with both endogenous CD8+ and CD4+ T cell infiltrate. We believe site-specific antigen heterogeneity represents a novel attribute for human melanoma metastases that should be considered when assessing the responsiveness to antigen specific therapies.
Introduction
Cancer metastases can demonstrate cellular heterogeneity between synchronous tumors (interlesional heterogeneity) and within individual tumors (intralesional heterogeneity) (1) . This phenomenon is thought to be driven by the stochastic genetic instability of tumor cell clones combined with the non-stochastic selective pressures of the host and tumor microenvironment (1) (2) (3) . Early evidence for metastatic tumor heterogeneity in animal models (4, 5) has been substantiated by more recent high resolution deep sequencing analyses of human tumors (6) .
Metastasis heterogeneity, thus, presents a significant obstacle to the current developmental paradigm for highly targeted molecular and immune based therapeutics for patients with metastatic cancer. Studies of cutaneous melanoma provide a distinctive opportunity to gain further insight into the nature of human metastasis heterogeneity. Melanoma metastases have been shown to have a high mutation frequency (7, 8) , diverse phenotype (4, 9), a clinically diffuse dissemination pattern (10) , and a unique ability to elicit spontaneous antigen specific host immune responses (11, 12) . As highly targeted immune therapies are currently in development for the treatment of metastatic melanoma, an improved understanding of metastasis heterogeneity is critical to assessing potential tumor susceptibility in future clinical studies.
To allow facile, reproducible, and specific profiling of the tumor cells within individual metastases, we utilized established immunohistochemical methods to perform semi-quantitative assessment for a panel of prototypic melanocyte differentiation antigens (MDAs) including gp100 (13, 14) , MART-1 (13, 14) , and tyrosinase (TYR) (15) . These tumor lineage antigens serve as favorable profiling markers given their high expression in normal melanocytes and primary melanoma tumors, but heterogeneous expression in metastatic lesions (16) (17) (18) (19) . T cell recognition and clearance of MDA expressing cells (immunoediting) has been implicated as a Tissue samples were prepared using two methods. First, multiple radial passage FNAs were performed using a 22-or 23-gauge needle to aspirate in situ lesions or freshly resected tumors.
The aspirate was diluted in RPMI medium 1640 (GIBCO BRL, Grand Island, NY) and cytospins were prepared. Second, samples of surgically resected tumor specimens were prepared by freezing in OCT compound (Miles, Elkhart, IN). Frozen tissue was then sectioned and evaluated for the presence of tumor using hematoxylin and eosin staining. Evaluation of antigen expression by FNA has been described previously to correlate highly with antigen expression evaluated by frozen section (14, 24) .
Immunohistochemistry.
Throughout the duration of the study, all staining was performed by a single cytopathology technician (P.A.F.). Melanoma antigen immunoreactivity of tumor cells in the biopsy specimens was assessed on acetone-fixed cytospins or frozen tissue sections by using antibodies against gp100 (clone HMB45), MART-1 (clone M2-7C10), and tyrosinase (clone T311). A negative sample control (purified myeloma protein, mouse IgG1 kappa; Organon Teknika Corporation, Durham, NC) and positive controls (melanoma cell lines) were performed throughout the study period. A modified avidin-biotin procedure (Vector Laboratories, Burlingame, CA) was performed, with either 3,3-diaminobenzidine or, in the case of highly pigmented samples, 3-amino-9-ethylcarbazole as the chromogen. MHC expression of tumor cells in the biopsy specimens was assessed using antibodies against MHC class I (Clone W6/32) and MHC class II (Clone 4A12). Lesions were categorized as negative (no positive cells), 1-25% (one positive cell or more), 25-50%, 50-75%, and >75% according to the percentage of cells expressing a given antigen. Lymphocytic infiltrate in the biopsy specimens was assessed by using antibodies against CD4 and CD8 (Coulter Becton-Dickinson). Infiltrate was graded on a 0-3+ scale. All specimens were prospectively assessed by a consistent group of board certified cytopathologists in the Department of Cytopathology/NIH using established standardized criteria and the results were serially recorded in a prospectively established database.
Statistical Analysis.
For descriptive analytic purposes, the antigen expression trend for a staining distribution was determined using the slope resulting from a simple linear regression of the percent of tumors with a given expression level vs. the categorized expression levels, identified as 0=absent, 1=1-25%, 2=25-50%, 3=50-75%, and 4≥75%. The associations between the slopes so obtained and the ordered CD4+ or CD8+ T cell infiltration levels were determined by a Spearman correlation.
The correlation would be interpreted primarily according to the magnitude of the correlation coefficient: |r| >0.70 is strong correlation; 0.50 < |r| < 0.70 is moderately strong correlation; 0.3 < |r| < 0.5 is weak to moderately strong correlation, and if |r| <0.3, then this would be considered weak correlation. The p-values associated with correlation coefficients are tests of whether r=0 and are of less importance. As these correlations were done based on the slopes for a T cell infiltrate category, and there were only 4 categories for each T cell infiltrate (0 to 3+), they should be interpreted as approximate indicators of the strength of the relationship. Associations between expression levels or between expression levels and infiltrate scores were determined using a Jonckheere-Terpstra test for trend (25) . A small p-value would indicate that the two measures were related to one another. In addition, a marginal homogeneity test was used to assess the discordance between paired categorical expression levels between two compared levels. The fractions without expression were compared between antigens in a pairwise fashion using McNemar's test for paired categorical data. A Kruskal-Wallis test was used to determine if the expression levels or lymphocytic infiltrates varied according to site. For those expression levels or infiltrates in which there was found to be significant variation by site, individual pairwise tests of sites were also performed using a Cochran-Armitage test for trend (26) .
Hierarchical cluster analysis utilizing between group linkage was performed using DendroUPGMA (27) . The program calculates the root-mean-square deviation (RMSD) between pairs of sets of variables, transforms these coefficients into distances and makes a clustering using the Unweighted Pair Group Method with Arithmetic mean (UPGMA) algorithm (28) .
Unrooted dendrograms were generated to illustrate the clustering of anatomic sites with similar antigen expression. The length of branching is inversely proportional to the antigen similarities between sites. Analyses were performed using SAS version 9.3 (SAS Institute, Cary NC), factor (MITF) (29, 30) . However, we did observe metastases with discordant antigen expression: 25% in MART vs. gp100, 34% in gp100 vs. TYR, and 36% in MART vs. TYR. The lesions with discordant MART and gp100 expression were evenly distributed between having high MART and low gp100 (12%) and low MART and high gp100 expression (13%). In contrast, the coexpression plots for TYR revealed that the discordant lesions demonstrated absence of TYR twice as often as gp100 (23% vs. 11%) and MART (24% vs. 12%). Cumulatively, these findings demonstrated that melanoma metastases have significant interlesional heterogeneity in MHC and MDA expression with discordant MDA expression in approximately one third of lesions, and more frequent absence of TYR expression when compared to MART and gp100.
MDA and MHC II expression in metastases demonstrate a site-specific pattern.
To determine if the observed tumor heterogeneity varied by location of the metastases in Table 1 ). Antigen expression was more variable for ST/SQ and LN metastases which demonstrated a trend toward higher percentages of stained cells for gp100 (slope=+1.7 and +1.9, respectively) and MART (slope=+3.5 and +3.7, respectively), but lower expression of TYR (slope=-1.4 and -1.9, respectively). Individual pairwise comparison of ST/SQ and LN metastases demonstrated that each of these sites also had higher gp100 and MART expression compared to liver and lung metastases (p<0.05) (Supplementary Table 1 ). Tumor cell expression of MHC class I was high across all sites (slope range: +6.8 to +11.7) with no significant site specific variability (p=0.41).
MHC II expressing tumor cells were less commonly found in the metastases, however, its Figure 3B, Supplementary Table 3) . Further, ST/SQ and LN metastasis, again, formed a discrete soft tissue/nodal cluster based upon shared expression of gp100 and MART which was distinct from a visceral cluster that included lung and liver metastases expressing the same antigens. Interestingly, the TYR expression in ST/SQ and LN metastases did not cluster with the other two MDAs, but had an expression pattern that was more akin to gp100 and MART expression in visceral metastases. In addition, the TYR expression in lung and liver tumors segregated independently and away from the main visceral cluster. Based upon these findings, we concluded that antigen expression in melanoma metastases clustered in a site specific phylogenetic pattern, but TYR expression in soft tissue/nodal and visceral sites clustered independently from gp100 and MART. To determine the magnitude and significance of these antigen profile differences, we performed statistical comparisons of the expression patterns for these unique site clusters ( Figure 3C, Supplementary Figure 1) . Analysis for each of the Table 4 ). In sum, these findings supported a nonstochastic stratified pattern of MDA expression that was highest in brain metastases, intermediate in soft tissue/nodal metastases, and lowest in visceral metastases. Notably, the expression profile for gp100 and MART were similar, but TYR antigen expression in sites outside of the brain was distinctly lower than the other two antigens.
TYR is uniquely correlated with both CD4+ and CD8+ T cell infiltrate.
To explore if the observed loss and variation in TYR expression may be a result of host immune targeting, we next sought to define the relationship between antigen expression with CD8+ and CD4+ T cell infiltration. Lymphocytic infiltrate was categorically scored from 0 (no infiltrate) to 3+ (high infiltrate). The antigen expression trend for each level of CD8+ and CD4+ lymphocytic infiltrate was determined (Supplementary Figure 2) and used to rank the expression associated with each degree of T cell infiltration. Based on overall expression levels, there were strong ordered associations between CD8+ T cell infiltration and MART, TYR, and MHC II expression in the metastases (each r=1.00; p<0.0001; Figure 4A ). Interestingly, TYR was the only marker that demonstrated a strong association with CD4+ T cell infiltration (r=1.00; p<0.0001; Figure 4B ). We concluded that the exclusive correlation of TYR expression with both CD8+ and CD4+ T cell infiltrate could be consistent with immunoediting as the mechanism for the selective loss of TYR among the metastases. 
Discussion
From the prospective analyses of over 3000 human melanoma metastases, we demonstrate an anatomic site-specific pattern of melanocyte differentiation antigen expression with the highest levels seen in brain, intermediate levels in soft tissues/lymph nodes, and lowest levels in visceral metastases. Although heterogeneity of metastases has been well described (16) (17) (18) (19) , to our knowledge, a determined pattern of tumor antigen expression based upon anatomic site of metastasis has not been previously demonstrated in humans. Conceptually, metastatic heterogeneity is thought to result from stochastic genetic and epigenetic events under selective pressure exerted by the host and tumor microenvironment. This theory is based upon our understanding of the metastatic process as described originally by Paget's "seed and soil" hypothesis (31) , and refined by work from Fidler, and others, in animal models (1, 32) . Sitespecific interactions between the "seed" and "soil" could partially explain the tumor heterogeneity at different anatomic sites found in our study. In fact, the observation that brain metastases have the highest MDA expression is particularly consistent with early studies in nude mice which demonstrated that melanoma brain metastases were uniformly pigmented compared to the variable pigmentation of tumors observed at other metastatic sites (4) . In contrast to these immune deficient animal models, here we sought to explore the interplay of the immune response with metastatic heterogeneity. Immunoediting, whereby antigen expressing cells are selectively eliminated or antigens are reversibly lost as an escape mechanism has been demonstrated in several animal models (20-23, 33, 34) . However, the in vivo association of specific tumor antigens and MHC expression with natural endogenous immune responses has not been clearly demonstrated human. In a large cohort of melanoma metastases, we observed a significant association between tumor expression of MHC II (not MHC I) and CD8 infiltrate. We reduced in both liver and lung tumors when compared to cutaneous tumors. Further, they noted a concomitant natural induction of CD8+ T cells specific for both TYR and TRP2, suggesting that the visceral tumors, rather than the cutaneous tumors, were preferentially subjected to immunoediting by antigen specific T cells. In another murine study, a vaccine targeting normal melanocytes induced polyclonal T cell responses that resulted in the generation of B16 melanoma escape variants which grew aggressively in vivo, became amelanotic, and preferentially lost expression of TYR and TRP2, but maintained expression of other melanomaassociated antigens, such as gp100 (38); a finding that directly parallels our human observations. Collectively, our current profiling of human metastasis antigen expression and immune infiltrate provides compelling evidence for a non-stochastic distribution of antigen expression based upon anatomic site. Although our study focused on the well-described MDAs, these results may warrant future investigation into the site-specific expression of a wide variety of antigens including mutated antigens and cancer-testis antigens, as well as the intratumoral heterogeneity of these antigens in individual metastases. The broad implications of our study would further support that clinicians utilizing immunotherapeutics -and potentially other targeted therapiesshould consider that target assessment within metastasis is highly contingent on the anatomic site of biopsy. Ideally, biopsies should be obtained from the sites of disease anticipated to be most influential on the eventual outcome of the patient. Further, tracking antigen loss in tumors should be performed on the same lesion to avoid the confounding variable of interlesional heterogeneity.
In sum, the cumulative findings in this report support that future clinical effort utilizing targeted immune therapies must account for site specific heterogeneity when assessing their use and impact on metastases.
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